Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus
Background Optogenetic tools allow precise manipulation of neuronal activity via genetically encoded light-sensitive proteins. Currently available optogenetic inhibitors are not suitable for prolonged use due to short-lasting photocurrents, tissue heating, and unintended changes in ion distributions...
Gespeichert in:
Veröffentlicht in: | BMC Biology 2022, Vol.20 (1) |
---|---|
Hauptverfasser: | , , , , |
Format: | Report |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | |
container_title | BMC Biology |
container_volume | 20 |
creator | Kleis, P Paschen, E Häussler, U Bernal Sierra, Y. A Haas, C. A |
description | Background Optogenetic tools allow precise manipulation of neuronal activity via genetically encoded light-sensitive proteins. Currently available optogenetic inhibitors are not suitable for prolonged use due to short-lasting photocurrents, tissue heating, and unintended changes in ion distributions, which may interfere with normal neuron physiology. To overcome these limitations, a novel potassium channel-based optogenetic silencer, named PACK, was recently developed. The PACK tool has two components: a photoactivated adenylyl cyclase from Beggiatoa (bPAC) and a cAMP-dependent potassium channel, SthK, which carries a large, long-lasting potassium current in mammalian cells. Previously, it has been shown that activating the PACK silencer with short light pulses led to a significant reduction of neuronal firing in various in vitro and acute in vivo settings. Here, we examined the viability of performing long-term studies in vivo by looking at the inhibitory action and side effects of PACK and its components in healthy and epileptic adult male mice. Results We targeted hippocampal cornu ammonis (CA1) pyramidal cells using a viral vector and enabled illumination of these neurons via an implanted optic fiber. Local field potential (LFP) recordings from CA1 of freely moving mice revealed significantly reduced neuronal activity during 50-min intermittent (0.1 Hz) illumination, especially in the gamma frequency range. Adversely, PACK expression in healthy mice induced chronic astrogliosis, dispersion of pyramidal cells, and generalized seizures. These side effects were independent of the light application and were also present in mice expressing bPAC without the potassium channel. Light activation of bPAC alone increased neuronal activity, presumably via enhanced cAMP signaling. Furthermore, we applied bPAC and PACK in the contralateral hippocampus of chronically epileptic mice following a unilateral injection of intrahippocampal kainate. Unexpectedly, the expression of bPAC in the contralateral CA1 area was sufficient to prevent the spread of spontaneous epileptiform activity from the seizure focus to the contralateral hippocampus. Conclusion Our study highlights the PACK tool as a potent optogenetic inhibitor in vivo. However, further refinement of its light-sensitive domain is required to avoid unexpected physiological changes. Keywords: bPAC, cAMP, Electrophysiology, Epilepsy, Kainate, Optogenetic inhibition |
doi_str_mv | 10.1186/s12915-021-01210-1 |
format | Report |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracacademiconefile_A693700237</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A693700237</galeid><sourcerecordid>A693700237</sourcerecordid><originalsourceid>FETCH-gale_infotracacademiconefile_A6937002373</originalsourceid><addsrcrecordid>eNqVT8tKBDEQDKLg-vgBT_0DWdMz7sY9iigePO59aTM9M5EkHSaZBS9-u7PgwavUoQrqAaXUHZo14uP2vmCzw402DWqDDRqNZ2qF9gG1Ncae_9GX6qqUT2OajbXtSn2_Sxp05SmCT3D0RwHKOXhH1UsC6YEgS6VS_BzBjZQSB_1BhTuQXGXgxNU7KD5wcjydVurIMDKFOn4BpQ44L2Y-paLMZfF8zuIo5rncqIueQuHbX75W69eX_fObHijwwade6kRuQcfRO0ncL1OHp-2uXb40rW3_XfgB5rRfsg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype></control><display><type>report</type><title>Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Kleis, P ; Paschen, E ; Häussler, U ; Bernal Sierra, Y. A ; Haas, C. A</creator><creatorcontrib>Kleis, P ; Paschen, E ; Häussler, U ; Bernal Sierra, Y. A ; Haas, C. A</creatorcontrib><description>Background Optogenetic tools allow precise manipulation of neuronal activity via genetically encoded light-sensitive proteins. Currently available optogenetic inhibitors are not suitable for prolonged use due to short-lasting photocurrents, tissue heating, and unintended changes in ion distributions, which may interfere with normal neuron physiology. To overcome these limitations, a novel potassium channel-based optogenetic silencer, named PACK, was recently developed. The PACK tool has two components: a photoactivated adenylyl cyclase from Beggiatoa (bPAC) and a cAMP-dependent potassium channel, SthK, which carries a large, long-lasting potassium current in mammalian cells. Previously, it has been shown that activating the PACK silencer with short light pulses led to a significant reduction of neuronal firing in various in vitro and acute in vivo settings. Here, we examined the viability of performing long-term studies in vivo by looking at the inhibitory action and side effects of PACK and its components in healthy and epileptic adult male mice. Results We targeted hippocampal cornu ammonis (CA1) pyramidal cells using a viral vector and enabled illumination of these neurons via an implanted optic fiber. Local field potential (LFP) recordings from CA1 of freely moving mice revealed significantly reduced neuronal activity during 50-min intermittent (0.1 Hz) illumination, especially in the gamma frequency range. Adversely, PACK expression in healthy mice induced chronic astrogliosis, dispersion of pyramidal cells, and generalized seizures. These side effects were independent of the light application and were also present in mice expressing bPAC without the potassium channel. Light activation of bPAC alone increased neuronal activity, presumably via enhanced cAMP signaling. Furthermore, we applied bPAC and PACK in the contralateral hippocampus of chronically epileptic mice following a unilateral injection of intrahippocampal kainate. Unexpectedly, the expression of bPAC in the contralateral CA1 area was sufficient to prevent the spread of spontaneous epileptiform activity from the seizure focus to the contralateral hippocampus. Conclusion Our study highlights the PACK tool as a potent optogenetic inhibitor in vivo. However, further refinement of its light-sensitive domain is required to avoid unexpected physiological changes. Keywords: bPAC, cAMP, Electrophysiology, Epilepsy, Kainate, Optogenetic inhibition</description><identifier>ISSN: 1741-7007</identifier><identifier>EISSN: 1741-7007</identifier><identifier>DOI: 10.1186/s12915-021-01210-1</identifier><language>eng</language><publisher>BioMed Central Ltd</publisher><subject>Analysis ; Care and treatment ; Cyclic adenylic acid ; Diagnosis ; Electrophysiology ; Epilepsy ; Gene silencing ; Health aspects ; Methods ; Potassium channels ; Risk factors</subject><ispartof>BMC Biology, 2022, Vol.20 (1)</ispartof><rights>COPYRIGHT 2022 BioMed Central Ltd.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,780,860,4476,27902</link.rule.ids></links><search><creatorcontrib>Kleis, P</creatorcontrib><creatorcontrib>Paschen, E</creatorcontrib><creatorcontrib>Häussler, U</creatorcontrib><creatorcontrib>Bernal Sierra, Y. A</creatorcontrib><creatorcontrib>Haas, C. A</creatorcontrib><title>Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus</title><title>BMC Biology</title><description>Background Optogenetic tools allow precise manipulation of neuronal activity via genetically encoded light-sensitive proteins. Currently available optogenetic inhibitors are not suitable for prolonged use due to short-lasting photocurrents, tissue heating, and unintended changes in ion distributions, which may interfere with normal neuron physiology. To overcome these limitations, a novel potassium channel-based optogenetic silencer, named PACK, was recently developed. The PACK tool has two components: a photoactivated adenylyl cyclase from Beggiatoa (bPAC) and a cAMP-dependent potassium channel, SthK, which carries a large, long-lasting potassium current in mammalian cells. Previously, it has been shown that activating the PACK silencer with short light pulses led to a significant reduction of neuronal firing in various in vitro and acute in vivo settings. Here, we examined the viability of performing long-term studies in vivo by looking at the inhibitory action and side effects of PACK and its components in healthy and epileptic adult male mice. Results We targeted hippocampal cornu ammonis (CA1) pyramidal cells using a viral vector and enabled illumination of these neurons via an implanted optic fiber. Local field potential (LFP) recordings from CA1 of freely moving mice revealed significantly reduced neuronal activity during 50-min intermittent (0.1 Hz) illumination, especially in the gamma frequency range. Adversely, PACK expression in healthy mice induced chronic astrogliosis, dispersion of pyramidal cells, and generalized seizures. These side effects were independent of the light application and were also present in mice expressing bPAC without the potassium channel. Light activation of bPAC alone increased neuronal activity, presumably via enhanced cAMP signaling. Furthermore, we applied bPAC and PACK in the contralateral hippocampus of chronically epileptic mice following a unilateral injection of intrahippocampal kainate. Unexpectedly, the expression of bPAC in the contralateral CA1 area was sufficient to prevent the spread of spontaneous epileptiform activity from the seizure focus to the contralateral hippocampus. Conclusion Our study highlights the PACK tool as a potent optogenetic inhibitor in vivo. However, further refinement of its light-sensitive domain is required to avoid unexpected physiological changes. Keywords: bPAC, cAMP, Electrophysiology, Epilepsy, Kainate, Optogenetic inhibition</description><subject>Analysis</subject><subject>Care and treatment</subject><subject>Cyclic adenylic acid</subject><subject>Diagnosis</subject><subject>Electrophysiology</subject><subject>Epilepsy</subject><subject>Gene silencing</subject><subject>Health aspects</subject><subject>Methods</subject><subject>Potassium channels</subject><subject>Risk factors</subject><issn>1741-7007</issn><issn>1741-7007</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2022</creationdate><recordtype>report</recordtype><sourceid/><recordid>eNqVT8tKBDEQDKLg-vgBT_0DWdMz7sY9iigePO59aTM9M5EkHSaZBS9-u7PgwavUoQrqAaXUHZo14uP2vmCzw402DWqDDRqNZ2qF9gG1Ncae_9GX6qqUT2OajbXtSn2_Sxp05SmCT3D0RwHKOXhH1UsC6YEgS6VS_BzBjZQSB_1BhTuQXGXgxNU7KD5wcjydVurIMDKFOn4BpQ44L2Y-paLMZfF8zuIo5rncqIueQuHbX75W69eX_fObHijwwade6kRuQcfRO0ncL1OHp-2uXb40rW3_XfgB5rRfsg</recordid><startdate>20220114</startdate><enddate>20220114</enddate><creator>Kleis, P</creator><creator>Paschen, E</creator><creator>Häussler, U</creator><creator>Bernal Sierra, Y. A</creator><creator>Haas, C. A</creator><general>BioMed Central Ltd</general><scope/></search><sort><creationdate>20220114</creationdate><title>Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus</title><author>Kleis, P ; Paschen, E ; Häussler, U ; Bernal Sierra, Y. A ; Haas, C. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-gale_infotracacademiconefile_A6937002373</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Analysis</topic><topic>Care and treatment</topic><topic>Cyclic adenylic acid</topic><topic>Diagnosis</topic><topic>Electrophysiology</topic><topic>Epilepsy</topic><topic>Gene silencing</topic><topic>Health aspects</topic><topic>Methods</topic><topic>Potassium channels</topic><topic>Risk factors</topic><toplevel>online_resources</toplevel><creatorcontrib>Kleis, P</creatorcontrib><creatorcontrib>Paschen, E</creatorcontrib><creatorcontrib>Häussler, U</creatorcontrib><creatorcontrib>Bernal Sierra, Y. A</creatorcontrib><creatorcontrib>Haas, C. A</creatorcontrib></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kleis, P</au><au>Paschen, E</au><au>Häussler, U</au><au>Bernal Sierra, Y. A</au><au>Haas, C. A</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus</atitle><jtitle>BMC Biology</jtitle><date>2022-01-14</date><risdate>2022</risdate><volume>20</volume><issue>1</issue><issn>1741-7007</issn><eissn>1741-7007</eissn><abstract>Background Optogenetic tools allow precise manipulation of neuronal activity via genetically encoded light-sensitive proteins. Currently available optogenetic inhibitors are not suitable for prolonged use due to short-lasting photocurrents, tissue heating, and unintended changes in ion distributions, which may interfere with normal neuron physiology. To overcome these limitations, a novel potassium channel-based optogenetic silencer, named PACK, was recently developed. The PACK tool has two components: a photoactivated adenylyl cyclase from Beggiatoa (bPAC) and a cAMP-dependent potassium channel, SthK, which carries a large, long-lasting potassium current in mammalian cells. Previously, it has been shown that activating the PACK silencer with short light pulses led to a significant reduction of neuronal firing in various in vitro and acute in vivo settings. Here, we examined the viability of performing long-term studies in vivo by looking at the inhibitory action and side effects of PACK and its components in healthy and epileptic adult male mice. Results We targeted hippocampal cornu ammonis (CA1) pyramidal cells using a viral vector and enabled illumination of these neurons via an implanted optic fiber. Local field potential (LFP) recordings from CA1 of freely moving mice revealed significantly reduced neuronal activity during 50-min intermittent (0.1 Hz) illumination, especially in the gamma frequency range. Adversely, PACK expression in healthy mice induced chronic astrogliosis, dispersion of pyramidal cells, and generalized seizures. These side effects were independent of the light application and were also present in mice expressing bPAC without the potassium channel. Light activation of bPAC alone increased neuronal activity, presumably via enhanced cAMP signaling. Furthermore, we applied bPAC and PACK in the contralateral hippocampus of chronically epileptic mice following a unilateral injection of intrahippocampal kainate. Unexpectedly, the expression of bPAC in the contralateral CA1 area was sufficient to prevent the spread of spontaneous epileptiform activity from the seizure focus to the contralateral hippocampus. Conclusion Our study highlights the PACK tool as a potent optogenetic inhibitor in vivo. However, further refinement of its light-sensitive domain is required to avoid unexpected physiological changes. Keywords: bPAC, cAMP, Electrophysiology, Epilepsy, Kainate, Optogenetic inhibition</abstract><pub>BioMed Central Ltd</pub><doi>10.1186/s12915-021-01210-1</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1741-7007 |
ispartof | BMC Biology, 2022, Vol.20 (1) |
issn | 1741-7007 1741-7007 |
language | eng |
recordid | cdi_gale_infotracacademiconefile_A693700237 |
source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SpringerLink Journals - AutoHoldings; PubMed Central Open Access; Springer Nature OA Free Journals |
subjects | Analysis Care and treatment Cyclic adenylic acid Diagnosis Electrophysiology Epilepsy Gene silencing Health aspects Methods Potassium channels Risk factors |
title | Long-term in vivo application of a potassium channel-based optogenetic silencer in the healthy and epileptic mouse hippocampus |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T22%3A43%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Long-term%20in%20vivo%20application%20of%20a%20potassium%20channel-based%20optogenetic%20silencer%20in%20the%20healthy%20and%20epileptic%20mouse%20hippocampus&rft.jtitle=BMC%20Biology&rft.au=Kleis,%20P&rft.date=2022-01-14&rft.volume=20&rft.issue=1&rft.issn=1741-7007&rft.eissn=1741-7007&rft_id=info:doi/10.1186/s12915-021-01210-1&rft_dat=%3Cgale%3EA693700237%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A693700237&rfr_iscdi=true |